Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:11:07 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Z:PFE - PFIZER INC - https://www.pfizer.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PFE - Z0.127.12·27.400.427.22+0.7352.850,688.51,367,160106,75126.67  27.37  26.5227.69  20.91519:59:5606:4515 min RT 2¢

Recent Trades - Last 10 of 106751
Time ETExPriceChangeVolume
19:59:56Z27.1550.6651
19:59:40Z27.1550.6651
19:59:12Z27.1550.6651
19:58:57Z27.15080.66084
19:58:29Z27.15070.660745
19:57:26Z27.15030.66035
19:57:18Z27.15850.66853
19:55:09Z27.160.671
19:54:36Z27.1550.6651
19:52:52Z27.150.66100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 06:45U:PFENews ReleaseFDA Grants Priority Review for HYMPAVZI(TM) (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
2026-02-05 19:09U:PFENews ReleasePfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
2026-02-03 06:45U:PFENews ReleasePfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
2026-02-03 06:40U:PFENews ReleasePfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
2026-01-10 10:00U:PFENews ReleasePfizer's BRAFTOVI(TM) Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
2026-01-05 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2025-12-18 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
2025-12-17 06:45U:PFENews ReleasePADCEV(TM) Plus Keytruda(TM) Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
2025-12-16 06:45U:PFENews ReleasePfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
2025-12-15 08:00U:PFENews ReleaseAdaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
2025-12-12 12:00U:PFENews ReleasePfizer Declares First-Quarter 2026 Dividend
2025-12-10 08:15U:PFENews ReleaseTUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
2025-12-09 06:30U:PFENews ReleasePfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
2025-12-06 17:15U:PFENews ReleaseHYMPAVZI(TM) (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
2025-12-01 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
2025-11-24 07:00U:PFENews ReleaseArvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
2025-11-21 13:24U:PFENews ReleaseU.S. FDA Approves PADCEV(TM) plus Keytruda(TM) for Certain Patients with Bladder Cancer
2025-11-13 11:26U:PFENews ReleasePfizer Completes Acquisition of Metsera
2025-11-12 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2025-11-05 17:08U:PFENews ReleasePfizer Responds to Delaware Chancery Court Ruling